Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors.

IF 0.9 4区医学 Q4 CLINICAL NEUROLOGY Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI:10.18071/isz.76.0339

Munir Kaya, Asude Aksoy, Gokhan Artas, Metin Kaplan

{"title":"Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors.","authors":"Munir Kaya, Asude Aksoy, Gokhan Artas, Metin Kaplan","doi":"10.18071/isz.76.0339","DOIUrl":null,"url":null,"abstract":"Background and purpose: Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 (IDO-1) has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker..Methods: n=75 patients in total, n=25 patients with low grade glial tumors (LGG, grade 1-2), n=25 patients with high grade glial tumors (HGG, grade 3-4), and n=25 persons with normal brain tissue as control group were included in this study. IDO-1 expression was categorized by using immunohistochemical staining in biopsy specimens as high (H) and low (L) groups among the patients with gliomas. We used a 95% percent confidence interval and p <0.05 to analyze the association between the degree of IDO-1 expression, clinicopathological characteristics, and survival rates in glioma patients. .Results: In HGG, IDO-1 levels were higher than in control brain tissue and LGG (p< 0.001). The mean overall survival (OS) was longer in the L-IDO-1 group (64.53 ± 3.34) in months (95% CI: 57.969-71.098) compared to the H-IDO-1 group (43.74 ± 4.36) in months, (95% CI: 35.218-52.330) (p< 0.05)..Conclusion: IDO-1 expression is an independent prognostic biomarker to predict  OS and progression in HGG. IDO-1 can be evaluated as an alternative instrument for precision medicine in the treatment of gliomas..","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ideggyogyaszati Szemle-Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18071/isz.76.0339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose:

Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 (IDO-1) has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker.

Methods:

n=75 patients in total, n=25 patients with low grade glial tumors (LGG, grade 1-2), n=25 patients with high grade glial tumors (HGG, grade 3-4), and n=25 persons with normal brain tissue as control group were included in this study. IDO-1 expression was categorized by using immunohistochemical staining in biopsy specimens as high (H) and low (L) groups among the patients with gliomas. We used a 95% percent confidence interval and p <0.05 to analyze the association between the degree of IDO-1 expression, clinicopathological characteristics, and survival rates in glioma patients.

Results:

In HGG, IDO-1 levels were higher than in control brain tissue and LGG (p< 0.001). The mean overall survival (OS) was longer in the L-IDO-1 group (64.53 ± 3.34) in months (95% CI: 57.969-71.098) compared to the H-IDO-1 group (43.74 ± 4.36) in months, (95% CI: 35.218-52.330) (p< 0.05).

Conclusion:

IDO-1 expression is an independent prognostic biomarker to predict
OS and progression in HGG. IDO-1 can be evaluated as an alternative instrument for precision medicine in the treatment of gliomas.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

吲哚胺2，3-二加氧酶-1在神经胶质瘤中的表达对预后的价值。

背景与目的：胶质瘤是成人最常见的原发性中枢神经系统恶性肿瘤，预后不良。吲哚胺2，3-二加氧酶-1（IDO-1）在癌症免疫治疗中具有重要作用，因为它能使癌症细胞逃离免疫系统。在本研究中，我们旨在评估胶质瘤中IDO-1的表达与临床病理参数之间的相关性，以及IDO-1是否可以作为预后标志物。。方法：本研究共纳入75例患者、25例低级别神经胶质瘤（LGG，1-2级）、25例高级别神经胶质肿瘤（HGG，3-4级）和25例正常脑组织患者作为对照组。使用免疫组织化学染色将脑胶质瘤患者的活检标本中IDO-1的表达分为高（H）组和低（L）组。我们使用95%的置信区间，并且p<；0.05来分析脑胶质瘤患者IDO-1表达程度、临床病理特征和生存率之间的关系；。结果：在HGG中，IDO-1水平高于对照脑组织和LGG（p＜0.001）。L-IDO-1组（64.53±3.34）的平均总生存期（OS）在月内更长（95%CI:57.969-71.098），而H-IDO-1组合（43.74±4.36）在月间更长（95%CI:35.218-532.30）（p＜0.05）；de；预测的依赖性预后生物标志物；OS与HGG的进展。IDO-1可以是；被评估为精确医学治疗胶质瘤的替代仪器。。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ideggyogyaszati Szemle-Clinical Neuroscience CLINICAL NEUROLOGY-NEUROSCIENCES

CiteScore

1.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The aim of Clinical Neuroscience (Ideggyógyászati Szemle) is to provide a forum for the exchange of clinical and scientific information for a multidisciplinary community. The Clinical Neuroscience will be of primary interest to neurologists, neurosurgeons, psychiatrist and clinical specialized psycholigists, neuroradiologists and clinical neurophysiologists, but original works in basic or computer science, epidemiology, pharmacology, etc., relating to the clinical practice with involvement of the central nervous system are also welcome.